DRUG APPROVAL;
DRUG EXPOSURE;
DRUG MARKETING;
EUROPEAN UNION;
HUMAN;
INVESTIGATIVE PROCEDURES;
PHARMACOGENOMICS;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
REVIEW;
DRUG ADMINISTRATION;
DRUG INDUSTRY;
DRUG INTERACTION;
DRUG LABELING;
DRUG ADMINISTRATION SCHEDULE;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG INTERACTIONS;
DRUG LABELING;
EUROPEAN UNION;
HUMANS;
European Public Assessment Reports (EPARs).Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/.medicines/landing/epar-search.jsp&mid=WC0b01ac058001d124 [Last accessed 27 February 2015
ICH Topic E 4 Dose Response Information to Support Drug Registration.Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/.WC500002834.pdf [Last accessed November 1994
Directive 2001/83/EC of the european parliament and of the council of 6 November 2001 on the Community code relating to medicinal products for human use.Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir-2001-83-consol-2012/dir-2001-83-consol-2012en.pdf [Last accessed 6 November 2001
Postmarketing drug dosage changes of 499 fda-Approved new molecular entities 1980-1999
Cross J, Lee H, Westelinck A, et al.Postmarketing drug dosage changes of 499 FDA-Approved new molecular entities, 1980-1999.Pharmacoepidemiol Drug Saf 2002; 11: 439-46
A guideline on Summary of Product Characteristics (SmPC).Available from: http://ec.europa.eu/health/files/eudralex/.vol-2/c/smpc-guidelinerev2en.pdf [Last accessed September 2009
International Conference on Harmonisation Available from [Last accessed 09 November
International Conference on Harmonisation.Guidance for industry.dose-response information to support drug registration.Available from: http://.www.ich.org/products/guidelines/efficacy/.efficacy-single/article/dose-responseinformation-To-support-drug-registration.html [Last accessed 09 November 1994
Modelling and Simulation Working Group.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/.contacts/PDCO/peoplelisting-000123.jsp&mid=WC0b01ac058063f485
Concept paper on qualification and reporting of physiologically-based pharmacokinetic (PBPK) modelling and analyses.Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/06/.WC500169452.pdf [Last accessed 26 June 2014
Guideline on reporting the results of population pharmacokinetic analyses.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/.general/general-content-000370.jsp&mid=WC0b01ac0580032ec5
Guideline on the Investigation of Drug Interactions.Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/.WC500129606.pdf [Last accessed 21 June 2012
Pharmacogenomics EMA guidance.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/.general/general-content-000411.jsp&mid=WC0b01ac058002958e
Pharmacogenomic information in drug labels.european medicines agency perspective
Epub ahead of print
Ehmann F, Caneva L, Prasad K, et al.Pharmacogenomic information in drug labels.european medicines agency perspective.Pharmacogenomics J 2015.[Epub ahead of print
Draft guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products.Available from: http://www.ema.europa.eu/docs/en-GB/.document-library/Scientific-guideline/2014/01/WC500160232.pdf [Last accessed 10 January 2014
European Medicines Agency (EMA Available from Last accessed 04-05 December 2014
European Medicines Agency (EMA) workshop on the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/.newsandevents/events/2014/06/event-detail-000993.jsp&mid=WC0b01ac058004d5c3 [Last accessed 04-05 December 2014
EMA Scientific Advice and Protocol assistance.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/.regulation/general/general-content-000049.jsp&mid=WC0b01ac05800229b9
EMA Paediatric-medicine development.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/.general/general-content-000414.jsp&mid=WC0b01ac0580025b8d
EMA guidance on Marketing Authorisation Applications.Available from: http://www.ema.europa.eu/ema/.index.jsp?curl=pages/regulation/general/.general-content-000197.jsp&mid=WC0b01ac058002251c
Qualification of novel methodologies for medicine development.Available from: http://www.ema.europa.eu/ema/index.jsp?.curl=pages/regulation/general/general-content-000197.jsp&mid=WC0b01ac058002251c
Guideline on the procedure for accelerated assessment pursuant to article 39 (8) of regulation (EC) No 726/2004.Available from: http://www.ema.europa.eu/docs/en-GB/document-library/.Regulatoryand-procedural-guideline/2009/10/WC500005266.pdf [Last accessed 18 May 2006
Guideline on the scientific application and the practical arrangements necessary to implement commission regulation (ec) no 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of regulation (EC) No 726/2004.Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/10/.WC500004908.pdf [Last accessed 5 December 2006
Guideline on procedures for the granting of a marketing authorisation under exceptional circumstances, pursuant to article 14 (8) of regulation (EC) No 726/2004.Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatoryand-procedural-guideline/2009/10/WC500004883.pdf [Last accessed 15 December 2005
